Feryal Hajee, MD
Allergy · Little Silver, NJNPI 1841438447
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,583 of the $10,079 with a category attached, or 65.3%. 32 manufacturers reported payments, led by Pharming Healthcare, Inc. at 24.7% of the total. Reporting peaked in 2021 at $4,141 and has fallen 65.5% since, to $1,429 in 2025.
Across 371 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$2K
- AstraZeneca$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- GSK$803
- Pfizer$362
- Regeneron Healthcare Solutions, Inc.$290
- plus $2K from 26 others
What the payments were for
- Consulting fees$1,21812%
- Speaking & faculty fees$2,25022%
- Food & beverage$6,58365%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 16 | $2,489 |
| AstraZeneca | 83 | $2,403 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $1,527 |
| GSK | 70 | $803 |
| Pfizer | 19 | $362 |
| Regeneron Healthcare Solutions, Inc. | 18 | $290 |
| Grifols USA, LLC | 17 | $283 |
| CSL Behring | 16 | $260 |
| Amgen(2 entities) | 15 | $207 |
| Sanofi | 12 | $181 |
| Biocryst US Sales Co., LLC | 12 | $179 |
| Genentech USA, Inc. | 10 | $153 |
| Novartis | 7 | $117 |
| E.r. Squibb & Sons, L.L.C. | 1 | $114 |
| Cycle Pharmaceuticals Inc | 4 | $74 |
| Boehringer Ingelheim | 6 | $72 |
| Optinose US, Inc. | 4 | $58 |
| AbbVie | 4 | $54 |
| Aimmune Therapeutics, Inc. | 3 | $53 |
| Alk-abello, Inc | 4 | $50 |
| Blueprint Medicines Corporation | 3 | $42 |
| Incyte Corporation | 3 | $42 |
| Octapharma USA, Inc. | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $34 |
| Organon | 4 | $30 |
| Kaleo, Inc. | 2 | $26 |
| Shire North American Group Inc | 2 | $25 |
| Pulmonx Corporation | 1 | $22 |
| ADMA Biomanufacturing LLC | 1 | $18 |
| LEO Pharma Inc. | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,079 in reported general payments places this provider in the 65th percentile of 35 allergy providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $114,794 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 15 | $93,924 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 14 | $91,591 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $60,989 |
| Spiriva RespimatTiotropium Bromide | 25 | $12,816 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $11,920 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,742 |
| Montelukast Sodium | 50 | $953 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $523 |
| Azelastine Hcl | 11 | $474 |
| Fluticasone Propionate | 22 | $463 |
| Omeprazole | 19 | $167 |
| Prednisone | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $260 | $114,79413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,527 | $93,92415 claims |
| PfizerPanzyga | $362 | $91,59114 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $803 | $72,908117 claims |
| Boehringer IngelheimSpiriva Respimat | $72 | $12,81625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 allergy providers in New Jersey.
Other allergy in Little Silver
- John OppenheimerCedar Knolls$922K
- Jeffrey WeissRiverdale$532K
- Jay KashkinFair Lawn$436K
- Gregory TociMarlton$317K
- Eugene GattiMarlton$43K
- Howard DruceSomerville$37K
- Shashank ShethVoorhees$33K
- Donatella GraffinoCedar Knolls$15K
- Maria Lania-HowarthVoorhees$12K
- Jamie ZachariasSewell$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.